It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.
Testing new targeted drugs for retinoblastoma to find new treatment options.
Looking at the molecular effects inside Acute Myeloid Leukaemia cells treated with a specific new drug and investigating if the drug can be combined with other standard treatments.
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
This work focuses on defining how a new oncoprotein (called CARM1) we have discovered in neuroblastoma cells helps the cancer cells to survive, grow and avoid death.
By helping CCLG to fund live-saving research, our corporate partners are helping to shape a future where all children with cancer survive and live long healthy and independent lives.
Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
